[{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Vernakalant Hydrochloride","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Correvio Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Correvio Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Correvio Pharma \/ Advanz Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for Vernakalant Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Advanz Pharma believes that Correvio's niche portfolio, consisting of an established brand, and two growing, patent-protected brands, plus a pipeline of potential product launches, are highly complementary to its current priorities and future focus.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $76.0 million

                          May 27, 2020

                          Lead Product(s) : Vernakalant Hydrochloride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Advanz Pharma

                          Deal Size : $76.0 million

                          Deal Type : Acquisition

                          blank